GILD logo

Gilead Sciences, Inc.

GILD
Healthcare|Drug Manufacturers - General|US
$166.89
-0.68 (-0.41%)
DCF Value
$137.19
Cash / Share
$5.18

About

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

Stock Price

+35.2%(1Y)
1M
+13.5%
3M
+25.3%
6M
+27.1%
YTD
+36.0%
1Y
+41.3%
3Y
+114.2%
5Y
+153.0%

Pipeline Summary

536 total trials
102
Phase 1
174
Phase 2
127
Phase 3
66
Phase 4
Recruiting: 32Completed: 328Withdrawn: 16Terminated: 66Active: 42Not Yet Recruiting: 12Unknown: 28Approved: 6Available: 2Suspended: 2By Invitation: 1No Longer Available: 1

Active Trials (74)

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654Triple Negative Breast Cancer
Phase 3Recruiting
Enrollment: 1,514 participants
REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE
NCT07476339HIV -1 Infection
Phase 4Recruiting
Enrollment: 200 participants
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
NCT05396885Multiple Myeloma
Phase 2Active
Enrollment: 136 participants
Scalp Cooling in MBC
NCT04986579Metastatic Breast Cancer
Phase 2Recruiting
Enrollment: 120 participants
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05633667Lung Cancer
Phase 2Active
Enrollment: 192 participants

BioScore

6.9/10
Buy

Key Facts

Market Cap$207.00B
Employees17,000 (-3% YoY)
CEODaniel O'Day
IPO DateJan 22, 1992
Beta0.36
52-Week Range$116.88 – $176.58
Avg Volume6,374,205
ExchangeNASDAQ
Websitegilead.com

Ownership

Float99.8%
Shares Outstanding1240.3M

Recent Insider Trades

O'Day Daniel PatrickOPTION EX.
Nov 4, 2026102,619 shares @ $72.34
O'Day Daniel PatrickOPTION EX.
Nov 5, 20269,810 shares @ $72.34
O'Day Daniel PatrickSELL
Nov 4, 2026102,619 shares @ $175.16
O'Day Daniel PatrickSELL
Nov 5, 20269,810 shares @ $175.17
O'Day Daniel PatrickOPTION EX.
Nov 4, 2026102,619 shares @ $72.34

Peers

ABBVAbbVie Inc.
$514.78B
AZNAstraZeneca PLC
$289.14B
GSKGSK plc
$102.02B
JNJJohnson & Johnson
$664.95B
LLYEli Lilly and Company
$1273.77B
MRKMerck & Co., Inc.
$361.96B
NVSNovartis AG
$307.00B
PFEPfizer Inc.
$167.51B
Data last updated: Nov 9, 2026, 04:11 AM